Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 4/20 | 0.64 |
| ▸ | NAT1 | P18440 | 5/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | MYC | P01106 | 1/20 | 0.56 |
| ▸ | MAX | P61244 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | IDH1 | O75874 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.52 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL622204 | 1.00 | PIM1 (0.64) | PIM1NAT1CA2EPHX1ALDH1A1 | |
| SCHEMBL622203 | 1.00 | PIM1 (0.64) | PIM1NAT1CA2EPHX1ALDH1A1 | |
| SCHEMBL29764580 | 1.00 | PIM1 (0.64) | PIM1NAT1CA2EPHX1ALDH1A1 | |
| SCHEMBL2422392 | 0.87 | MEN1 (0.61) | PIM1NAT1ALDH1A1MAPTMEN1 | |
| SCHEMBL30343486 | 0.87 | MEN1 (0.61) | PIM1NAT1ALDH1A1MAPTMEN1 | |
| SCHEMBL1249878 | 0.87 | MEN1 (0.61) | PIM1NAT1ALDH1A1MAPTMEN1 | |
| SCHEMBL1249881 | 0.87 | MEN1 (0.61) | PIM1NAT1ALDH1A1MAPTMEN1 | |
| SCHEMBL15312912 | 0.84 | KDM4E (0.55) | PIM1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL622599 | 0.84 | KDM4E (0.55) | PIM1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL23600257 | 0.82 | CISD1 (0.58) | PIM1NAT1CA2EPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-04-27 | — | — | US | claimed |
| EP-4083037-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | Yonsei University, University-Industry Foundation(UIF). (KR) | 2022-11-02 | — | — | EP | claimed |
| WO-2021133037-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | 연세대학교 산학협력단 | 2021-07-01 | — | — | WO | claimed |
| US-20070060606-A1 | Compounds and methods for modulating phosphodiesterase 10A | DALHOUSIE UNIVERSITY (CA) | 2007-03-15 | — | — | US | claimed |
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-04-27 | — | — | US | disclosed |
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-04-27 | — | — | US | disclosed |
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-04-27 | — | — | US | disclosed |
| EP-4083037-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | Yonsei University, University-Industry Foundation(UIF). (KR) | 2022-11-02 | — | — | EP | disclosed |
| US-9598395-B2 | Premature-termination-codons readthrough compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598395-B2 | Premature-termination-codons readthrough compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-21 | — | — | US | disclosed |
| US-9255088-B2 | Premature-termination-codons readthrough compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-02-09 | — | — | US | disclosed |
| US-9255088-B2 | Premature-termination-codons readthrough compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-02-09 | — | — | US | disclosed |
| US-20130274283-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130274283-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-17 | — | — | US | disclosed |
| WO-2012021707-A2 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012021707-A2 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-16 | — | — | WO | disclosed |
| US-20090204336-A1 | PDZ-Domain Modulators | FORSCHUNGSVERBUND BERLIN E. V. (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20070060606-A1 | Compounds and methods for modulating phosphodiesterase 10A | DALHOUSIE UNIVERSITY (CA) | 2007-03-15 | — | — | US | disclosed |
| US-20070060606-A1 | Compounds and methods for modulating phosphodiesterase 10A | DALHOUSIE UNIVERSITY (CA) | 2007-03-15 | — | — | US | disclosed |
| US-20070060606-A1 | Compounds and methods for modulating phosphodiesterase 10A | DALHOUSIE UNIVERSITY (CA) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060606-A1 | Compounds and methods for modulating phosphodiesterase 10A | PDE7A, PDE10A, PDE2A | PIM1 2376/4885NAT1 875/4885CA2 3652/4885 |
| US-20130274283-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | UPF1, NUDT21, RNGTT | PIM1 3392/4885NAT1 1223/4885CA2 4884/4885 |
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | MAPT, APP, PRNP | PIM1 3071/4885NAT1 1239/4885CA2 3114/4885 |
| US-20090204336-A1 | PDZ-Domain Modulators | PDLIM5, DVL1, PSD | PIM1 1210/4885NAT1 4324/4885CA2 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.